• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Recent Advances in the Study of 1,4-Bis(4-bromophenoxy)butane (CAS: 34932-24-6) in Chemical Biology and Pharmaceutical Research

The compound 1,4-Bis(4-bromophenoxy)butane (CAS: 34932-24-6) has recently gained significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This aromatic ether compound, characterized by its brominated phenoxy groups connected by a butane linker, has demonstrated interesting biological activities that warrant further investigation. Recent studies have explored its role as a building block for more complex pharmaceutical agents, as well as its direct biological effects.

Structural analysis reveals that the symmetrical nature of 1,4-Bis(4-bromophenoxy)butane contributes to its molecular recognition properties. The bromine atoms at the para positions of the phenyl rings enhance the compound's ability to participate in halogen bonding, a feature that has been exploited in crystal engineering and drug design. Researchers have utilized this compound as a versatile intermediate in the synthesis of various biologically active molecules, particularly those targeting protein-protein interactions.

In pharmacological studies, 1,4-Bis(4-bromophenoxy)butane has shown promising activity as a modulator of certain enzymatic pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its inhibitory effects on specific kinases involved in inflammatory processes, suggesting potential applications in developing anti-inflammatory therapeutics. The compound's lipophilicity, conferred by its aromatic brominated groups, contributes to its favorable membrane permeability, an important characteristic for drug candidates.

Recent synthetic chemistry advancements have focused on developing more efficient routes to produce 1,4-Bis(4-bromophenoxy)butane with higher yields and purity. A novel catalytic system reported in Advanced Synthesis & Catalysis (2024) enables the synthesis of this compound under milder conditions, reducing the environmental impact of its production. These methodological improvements are crucial for scaling up production while maintaining the compound's structural integrity for pharmaceutical applications.

Toxicological assessments of 1,4-Bis(4-bromophenoxy)butane have progressed significantly in the past year. Preliminary in vitro studies indicate a favorable safety profile at therapeutic concentrations, though comprehensive in vivo studies are still ongoing. Researchers are particularly interested in understanding the compound's metabolic fate and potential for bioaccumulation, given its brominated aromatic structure.

The future research directions for 1,4-Bis(4-bromophenoxy)butane appear promising, with several groups investigating its potential in targeted drug delivery systems and as a scaffold for developing novel antimicrobial agents. Its unique combination of chemical stability and biological activity makes it an attractive candidate for further pharmaceutical development. Continued research is expected to uncover additional therapeutic applications and optimize its pharmacological properties for clinical translation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)